Specifically, PPARγ activation or PPARγ agonists have displayed beneficial effects on multiple asthma features, suppressing airway hyperresponsiveness, reducing inflammatory cell infiltration and epithelial hyperplasia in the airway, decreasing inflammatory mediator synthesis and release, inhibiting collagen deposition, and reducing mucus hypersecretion [23–25, 53, 54]. The gene discussed is PPARG; the disease is airway hyperresponsiveness.